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1. Background 
 
 
1.1 Percutaneous valved stent implantation 
With the ageing of the population, more and more multimorbid old patients with heart valve 
disease will appear in the next decades. Minimimally invasive interventions such as 
percutaneous valved stent implantation could become an alternative for them. Percutaneous 
valved stent implantation is the technique of a foldable heart valve that can be mounted on an 
expandable stent delivered percutaneously through standard catheter-based techniques and 
implanted within a diseased valve annulus (Lutter et al., 2004). In 1992, Andersen et al. 
reported on the first expandable valved stent implantation in a pig (Andersen et al., 1992). In 
the same year, Pavcnik et al. implanted a self-expanding caged-ball aortic valve into a dog’s 
heart (Pavcnik et al., 1992). Since then, percutaneous valve implantation had been rapidly 
developed in the following decade. In 2000, Bonhoeffer et al. reported on their long term 
study of percutaneous pulmonary valve implantation in lambs. An expandable stent with 
bovine jugular vein valves was delivered antegradly through the jugular vein into the native 
pulmonary valve position (Bonhoeffer et al., 2000). The same research group was the first to 
perform percutaneous pulmonary valve implantation in human (Bonhoeffer et al., 2002). 
Different studies of percutaneous aortic valve implantation were reported by Lutter et al. 
(Lutter et al., 2002) and Boudjemline et al. (Boudjemline and Bonhoeffer 2002) in 2002. First 
percutaneous aortic valved stent implantation in human was performed on a 57 year old man 
with calcific aortic stenosis and no other treatment option by Cribier et al. in 2002 (Cribier et 
al., 2002). Subsequently, Cribier et al. reported 6 cases of percutaneous aortic valved stent 
implantation in patients with calcific aortic stenosis in 2004 (Cribier et al., 2004). To date, 
percutaneous pulmonary and aortic valved stent replacement has already developed into an 
alternative to conventional surgery in selected patients (Hernandez et al., 2012).  
 
 
1.2 Transcatheter mitral valved stent implantation 
In 2005, the feasibility of percutaneous tricuspid valved stent implantation was demonstrated 
by Boudjemline et al. (see Fig 1.1) (Boudjemline et al., 2005). In the same year, Ma et al. 
implanted the first self-expandable valved stent in mitral position via atrial access (see Fig 1.2) 
(Ma et al., 2005). But mild paravalvular leakage (PVL) and significant increase of mean 
transvalvular gradient and mean gradient across the left ventricular outflow tract (LVOT) 
were observed. In 2010, Bai et al. reported stent migration in their percutaneous tricuspid 
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valve implantation. In their study, the stent was anchored on the native annulus by its atrial 
and ventricular element (Bai et al., 2010) (see Fig 1.3).But challenges remain in this field. 
How to anchor the stent stably in the native mitral annulus? How to seal the gap between the 
stent and the native annulus? How to produce a stent with high foldability in order to 
minimize the size of the stent delivery catheter? Due to these problems, up to now, 
transcatheter mitral valved stent implantation has not been used clinically. 
 
 
 
Fig 1.1 The tricuspid valved stent of Boudjemline’s group; En face (A) and lateral (B) views of the newly designed stent 
before its covering, and after covering with a polytetrafluoroethylene membrane and mounting of a valve in the central 
tubular part (C). The stent is shown from the ventricular side with the valve closed (a picture excerpted from the article: Steps 
toward the percutaneous replacement of atrioventricular valves.) (Boudjemline et al., 2005). 
 
 
 
Fig 1.2 The stent of Ma’s group: The double-crowned valved stent. A porcine pulmonary valve has been sutured into a 
Dacron conduit. Then, two self-expandable nitinol Z-stents were sutured on the external surface of the prosthesis so that two 
self-expanding crowns were created for fixation (a picture excerpted from article: Double-crowned valved stents for off-pump 
mitral valve replacement.) (Ma et al., 2005). 
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Fig 1.3 Left lateral view of the stent after implantation: The stent was embedded in the native annulus by the double disk 
structure (a picture excerpted from article: An integrated pericardial valved stent special for percutaneous tricuspid 
implantation: an animal feasibility study.) (Bai et al., 2010). 
 
Recently, we reported our transapical tricuspid valved stent implantation with less PVL and a 
stable gradient (Iino et al., 2011). Our stent was anchored to the ventricular wall via four 
tethers attached to the ventricular column of the stent. A conventional button served as an 
anchorage for these tethers. The same stent fixation system was used in the study on 
transapical mitral valved stent implantation of our group (not yet published). In this study, our 
mitral valved stent and the stent fixation system were demonstrated to reduce PVL in an 
observation period of up to three months (see Fig 1.4) (not yet published). 
 
 
 
Fig 1.4  The stent (a) was anchored onto the apex by four tethers (b) and a conventional button(c). 
 
 
1.3 The AmplatzerTM
However, our transapical delivery system and ventricular fixation system required a small 
chest midline incision and ministernotomy (see Fig 1.5).  
 
 occluder 
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Fig 1.5  A midline incision should be done on the chest for stent delivery and fixation. 
 
Fortunately, Tozzi et al. showed a sutureless closure of the left ventricular access in their 
publication in 2007 (Tozzi et al., 2007). They successfully used nitinol AmplatzerTM septal 
occluder to seal the defect on the left ventricle of porcine hearts (see Fig 1.6). In 2011, an 
American group closed puncture defects on the left ventricle of human hearts by AmplatzerTM
Jelnin et al., 2011
 
occluder ( ) (see Fig 1.7). This small deformable occluder can be deployed 
via a 10 Fr catheter. In this study, it could pose as an anchor point for the stent fixation. It 
made it possible to fix and anchor the stent transcatheterly. 
 
 
 
Fig 1.6  The AmplatzerTM occluder used by Tozzi’s group: Front view of a 12 mm AmplatzerTM
Tozzi et al., 2007
 occluder with the 
pericardial cuff on the ventricular side. The device is mounted into a sheath to simulate the deployment of a 25 mm stented 
valve. Its deployment is driven by a semi rigid wire (a picture excerpted from article: Endoscopic off-pump aortic valve 
replacement: does the pericardial cuff improve the sutureless closure of left ventricular access?) ( ). 
 
 
 
5 
 
 
 
Fig 1.7  A: Double percutaneous transapical puncture. B: Deployment of 2 AmplatzerTM
Jelnin et al., 2011
 Duct Occluder devices closing a 
double puncture (white arrows) (a picture excerpted from article: Clinical experience with percutaneous left ventricular 
transapical access for interventions in structural heart defects a safe access and secure exit.) ( ). 
 
 
1.4 The aim of this study 
At present, mitral valve disease is the second most popular heart valve disease in Europe. 
With the ageing of the population, more and more multimorbid old patients with mitral valve 
disease will appear in the next decades. For most of these patients, conventional surgical 
operation would not be the best option. Minimimally invasive interventions could become an 
alternative for them. Up to now, no successful studies on non-invasive mitral valve 
replacement have been reported. In this study, we demonstrate the feasibility of percutaneous 
mitral valved stent implantation in vitro. 
The transvenous-transseptal approach has been successfully used clinically for transcatheter 
valve-in-valve implantation in mitral position (Gurvitch et al., 2011) (Azadani and Tseng 
2011). This study showed the feasibility of mitral valved stent implantation into the native 
mitral annulus via percutaneous transvenous-transseptal access.  
The transapical mitral valved stent implantation of our research group demonstrated the 
feasibility of the button fixation unit. It effectively reduced PVL and the possibility of stent 
migration. But the conventional button is made of nondeformable material. A small chest 
midline incision and ministernotomy have to be performed for the deployment of the button 
unit and the closure of the apical defect. However, the studies on sutureless closure of left 
ventricular access indicated it is possible to use AmplatzerTM occluder for the occlusion of 
minimal defects on the left ventricle. Moreover, the disk-shaped occluder can serve as an 
anchor point for the stent fixation unit. Thus, only a percutaneous transapical puncture is 
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required for the deployment of the occluder. 
If the stent and the occluder could be connected via these two percutaneous accesses, it would 
be possible to create a novel percutaneous mitral valved stent implantation system. In this 
thesis, a non-invasive transcatheter mitral valved stent implantation system will be presented 
and analyzed. 
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2. Materials and methods 
 
 
2.1 Materials 
Material Manufacturer 
One-Piece Angiographic Needle with 
Snap-on Wing, 50 mm 
Cordis Europa N.V., LJ Roden, Holland 
Pigtail Catheter, 5 Fr Cordis Europa N.V., LJ Roden, Holland 
Ballon Angiographic Catheter, 5 Fr Teleflex Medical B.V., Hilversum, 
Holland 
Teflon Wire, 0.035 Inch Cordis Europa N.V., LJ Roden, Holland 
Backup Wire, 0.035 Inch Boston Scientific 
AndraSnare, AS-20, 4 Fr 
Corporation, Saint Paul, 
MN, USA 
Andramed GmbH, Reutlingen, Germany 
Reusable Rat Tooth Grasping Forceps Olympus Corporation, Tokyo, Japan 
Ascendra Introducer Sheath Set, 14 Fr Edwards Lifesciences LLC, Irvine, CA, 
USA 
Ascendra Introducer Sheath Set, 24 Fr Edwards Lifesciences LLC, Irvine, CA, 
USA 
ETHICON® PROLENE® Ethicon INC, Somerville, NJ, USA  Polypropylen 
Surgical Suture, 5-0 
Topline Polyester Surgical Suture, 2-0 HP-medica GmbH, Augsburg, Germany 
Amplatzer® AGA Medical Corporation, Minneapolis, 
MN, Germany 
 Septal Occluder 
 
 
2.2 Reagents 
Reagent Manufacturer 
IMERON® Brocco Imaging Deutschland GmbH, 
Konstanz, Germany 
 350 Contrast Agent 
 
 
2.3 Instruments 
Instrument Manufacturer 
Rotary Pump Stöckert Instrumente GmbH, Munich, 
Germany 
Olympus ViseRA CLV-S40 Endoscope 
System 
Olympus Corporation, Tokyo, Japan 
Philips Biplane DCI Digital Angiography 
System  
Philips Medical Systems Nederland B.V., 
Eindhoven, Holland 
 
 
2.4 General procedural steps of percutaneous mitral valved stent implantation 
The first and most important step of this system development was the establishment of the 
“femoral vein-septum-apex guide wire track”. All the following procedural steps were 
performed along this track. The stent and the fixation tethers were loaded and crimped into a 
tubular stent delivery system. This system was advanced into the left ventricle percutaneously 
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and transseptally. Then the tethers were captured and pulled out of the chest transapically. 
Thus, with these tethers, the operator was able to deploy the stent and anchor it onto the apex. 
The guide wire and the tethers were threaded through the occluder which was subsequently 
pushed along the guide wire track and deployed in the ventricle apex later. After the stent has 
been deployed by pulling the tethers, the guide wire track can be removed. And so the main 
procedure of non-invasive percutaneous mitral valved stent implantation was finished.  
 
 
2.5 Device development 
In this study, we designed and developed three generations of percutaneous mitral valved 
stent implantation systems. These three generations had essentially the same procedural steps. 
But the specific details of each step were quite different. For better understanding, we divided 
this implantation system into six parts:  
1. Self-expandable nitinol stent  
2. Femoral vein-apex guide wire track establishment system  
3. Stent storage and delivery system 
4. Tethers capture system  
5. Occluder and fixation system 
6. Deployment of the stent 
 
 
2.5.1 Self-expandable nitinol stent 
The stent was designed by our group for the mitral position (see Fig 2.1). It consisted of two 
parts: a flat orbicular atrial fixation element, a tubular ventricular element. These two 
elements inclined at an angle of 110°. Three tethers (75 mm) were connected to the bottom of 
the ventricular element. The atrial and ventricular elements had diameters of 35 mm and 28 
mm, respectively. For the first in vitro experiment, the stent was non-valved.  
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Fig 2.1  A: Top view of the stent; B: Bottom view of the stent; C: Side view of the stent. 
 
 
2.5.2 Femoral vein-apex guide wire track establishment system 
The first step in this in vitro experiment was to undergo transapical puncture and subsequently 
insert a 10 Fr apical access sheath into the left ventricle (see Fig 2.2). Afterwards, a venous 
balloon catheter was delivered into the left ventricle via the left atrium. Two different systems 
were used and developed to catch the balloon catheter within the left ventricle and to pull it 
out of the heart via the apical access sheath. Thus, the track for delivering the stent can be 
established via replacing the balloon catheter by a stiff guide wire.  
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Fig 2.2  A: Transapical puncture was conducted by a puncture needle. B: A guide wire was inserted into the heart via the 
puncture needle. C, D: 10 Fr dilator and apical access sheath are guided along the guide wire and inserted into the left 
ventricle. Afterwards, the dilator and the guide wire were taken off. 
 
 
First generation track establishment system: “magnets capture system” 
This system included a venous balloon catheter and a transapical capture stick (see Fig 2.3). 
Both parts had a small magnet (2 mm in diameter and 1 mm in thickness) on the tip. Thus, the 
balloon catheter can be caught in the left heart by the magnet on the tip of the stick which was 
inserted into the heart transapically. After being towed into the apical puncture sheath, the 
balloon catheter can be easily pushed out of the chest along the transapical access sheath. 
Then, a vein-apex guide wire track system can be established by a stiff guide wire taking the 
place of the balloon catheter. 
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Fig 2.3  A, B: A tiny magnet (2 mm in diameter and 1 mm in thickness) was fixed onto the venous balloon catheter by 3-0 
polypropylene sutures. C: A magnet of the same size was embedded into the tip of a 5 Fr plastic stick. D: The balloon catheter 
can be caught by magnetic force. 
 
 
Second generation track establishment system: “snare capture system” 
This device has already been commonly used in the field of cardiac interventions. In this 
study, we used this snare device to catch the soft guide wire which was introduced together 
with the balloon catheter into the left ventricle (see Fig 2.4). Afterwards the soft guide wire 
was pulled out of the chest transapically. Then the balloon catheter was pushed out of the 
heart along the soft guide wire. The soft guide wire was exchanged by a stiff one and, 
therefore, the same vein-apex guide wire track system was established as in the first 
prototype. 
 
 
 
12 
 
 
 
Fig. 2.4  The snare capture system (a: the snare ring; b: the wire with a soft tip). 
 
 
2.5.3 Storage and delivery system for the stent and the fixation tethers 
The function of this system was to store and deliver the stent as well as the fixation tethers. 
Main part of the system was a 14 Fr catheter. Though, during the development of this system, 
the tip of the catheter was changed into different structures. Three different prototypes were 
developed in this study. 
 
 
The first generation stent delivery system 
This system consisted of a 14 Fr sheath, a distal plug, a 14 Fr proximal cover (in this paper, 
the proximal end of the applicator is the end which is nearer to the heart during using), a 6 Fr 
conical tip and a center lumen catheter (0.035-inch inner diameter) (see Fig 2.5). The 14 Fr 
sheath was the main part of this system. The collapsed stent together with the tethers were 
stored herein. Three 75 cm length tethers were repeatedly folded into a 4 cm bundle and 
inserted into the sheath. The silicon cover served as a lid to keep the tethers inside the sheath 
and to allow a smooth guidance of the delivery system, especially very important for the 
transseptal penetration. A ‘Y’ shaped incision was done on the top of the cover in order to 
generate a flap-like opening which cannot be opened till the tension on the tethers was strong 
enough to pull the stent out. The conical tip was the key part of this system. There was one 
suture loop at each end of the tip. The proximal one was for the tethers capture system which 
will be introduced later. And the second one was connected to the fixation tethers (see Fig 2.6). 
A plug was fixed onto the distal end of the sheath and a center lumen catheter went 
throughout the whole system. This center lumen allowed the passage of the guide wire and 
sustained the conical tip (Fig 2.5 C). The tip can be easily detached from the center lumen 
catheter after being caught by the tethers capture system. 
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Fig 2.5  A: This system consisted of a 14 Fr sheath (a), a distal plug (b), a 14 Fr proximal cover (c), a 6 Fr conical tip (d) 
and a center lumen catheter (e). B, C: The distal plug and the center lumen catheter supported the conical tip and allowed the 
passage of the guide wire. 
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Fig 2.6  A: the conical tip with one loop at both ends. B: the silicon cover with a ‘Y’ shaped opening. C: The stent was 
collapsed and mounted into the storage catheter and the fixation tethers were folded into a bundle and stored herein. D: The 
ends of the tethers were connected with the distal loop of the conical tip. E: The stent storage and delivery catheter was sealed 
by the silicon cover and the conical tip. 
 
 
The second generation stent delivery system 
This generation was modified from a 14 Fr venous access sheath and dilator (see Fig 2.7). The 
dilator was cut into two parts, one small tip and one longer part serving as a pusher. These two 
parts were connected by a center lumen catheter (10 cm in length, 0.035-inch inner diameter) 
which was cut from a pigtail catheter. The stent was collapsed and loaded in the space 
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between the pusher and the tip (see Fig 2.8). The three tethers were wound upwards around 
the center lumen catheter like a triple helix upwards to the tip. Theoretically, due to this 
structure, the tethers occupy less space and can be smoothly and orderly pulled out from the 
sheath. In addition, in this prototype, an 8 mm tube which was also cut from the pigtail 
catheter (0.035-inch inner diameter) played the same role as the tip of the first generation 
system. Though, the small proximal loop was replaced by two longer loops connected to a 
magnet (2 mm in diameter and 1 mm in thickness) at the end. The distal loop was also 
prolonged (see Fig 2.8 B). This short tube was inserted into the channel on the proximal end 
of the tip and could be easily pulled out (see Fig 2.8 D). In a sense, this tube is also one part 
of the center lumen catheter. The loop on the distal end of the tube went down along the 
outside of the tip to the interior of the sheath and was connected with the three fixation tethers. 
The details of the utility of the top loops with the magnet will be presented in the “tethers 
capture” section. 
 
 
 
Fig 2.7  The dilator was cut into two parts, one small tip (a) and the other worked as the pusher (b). These two parts were 
connected by a center lumen catheter (c). d: the 14 Fr venous access sheath 
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Fig 2.8  A: There was one suture loop at each end of the tip. A small magnet was fixed on the proximal loop (a). B: The 
distal loop was prolonged compare to that of the first generation. C: The three tethers wound upwards around the center 
lumen catheter like a triple helix up to the tip. D: The distal loop of the tube went down along the lateral surface of the tip till 
the interior of the storage sheath and, there, was connected with the three fixation tethers. 
 
 
The third generation stent delivery system 
The principal part of this prototype is the same as that of the second generation. But the 8 mm 
tube on the tip was replaced by a 35 cm center lumen catheter which was also cut from a pig 
tail catheter (0.035-inch inner diameter) (see Fig 2.9). This catheter did not contain any loop 
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or magnet. Though, there were three holes in the wall of its proximal side. Similarly, this 
center lumen catheter is separable as well. In this system, the collapsed stent was stored in the 
sheath. But the tethers were straightened and went upward along the conical tip till the tip of 
the center lumen catheter. There, they respectively passed through the three holes and then 
turned back (see Fig 2.10 A). Hence, the tethers were folded one time outside the sheath 
chamber along the separable lumen catheter. Afterwards, the lumen catheter and the tethers 
were totally ensheathed by a 37 cm soft dilator (10-Fr outer diameter, 6-Fr inner diameter). 
The lateral surface of the center lumen catheter and the medial surface of the soft dilator 
formed a tethers storage lumen (see Fig 2.10 B+C).  
 
 
 
Fig 2.9  The principal part of the prototype of the third generation was the same as that of the second generation but the 8 
mm tube was changed against a 35 cm one (a). A 37cm dilator was used (b).  
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Fig 2.10  A: The tethers were folded along the center lumen. B, C: The tethers were mounted in the storage lumen. 
 
 
2.5.4 Fixation tether capture system 
After the stent and the fixation tethers were delivered into the left ventricle, the tethers should 
be captured and taken out of the chest transapically. The tethers played a very important role 
in the implantation procedure. They were not only the anchor of the stent, but also the only 
bridge connecting the stent and the operator. The following steps - including deployments of 
the occluder and the stent - were both conducted by using the tethers. 
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The first generation capture system: “hook-loop” system 
As previously mentioned, our percutaneous mitral valved stent implantation system was based 
on a femoral vein-septum-apex guide wire track. For the establishment of this track, 
transvenous, transseptal and transapical punctures have to be performed. A vascular puncture 
sheath and a 10 French radial sheath were separately inserted into the femoral vein and into 
the apex for the following operations.  
The first generation of stent delivery system was advanced along the track into the left 
ventricle cavity till the tip of it got into the 10 French apical access sheath (see Fig. 2.11 A). A 
stiff metal wire, one end of which had been bent into a hook, was used to grapple the loop on 
the tip and to pull it out transapically together with the fixation tethers which had been 
attached on the other side of the tip (see Fig. 2.11 B). Consequently, we were able to perform 
the next steps outside the body with these tethers. 
 
 
 
 
Fig 2.11  A: The tip was pushed into the apical access sheath. (a: the apical access sheath). B: The tip and the tethers were 
caught and pulled out of the sheath by the hook. 
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The second generation capture system: “forceps-magnet-loop” system 
A reusable rat tooth grasping forceps, which was 2.8 mm in diameter, was used in this system 
(see Fig 2.12 A). The forceps was inserted into the left ventricle via the apical access sheath. 
When it met the stent delivery system in the ventricle cavity, a magnet on the tip of the 
delivery system guided the loops to the forceps (see Fig 2.12 B). It made the loops easily to be 
grasped by the forceps (see Fig 2.12 C). After being captured, the small tube with the tethers 
fixed on its end could be dragged out of the access sheath.  
 
 
 
 
 
Fig 2.12  A: The rat tooth grasping forceps are commonly used in interventional operations. B: The small magnet was held 
down by the forceps. C: The forceps can easily catch the loop after being pushed a few millimeters forward. 
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The third generation capture system: “hand capture” system 
The improvement of the tethers storage system made it possible to capture the tethers outside 
the heart. The 35 cm tethers storage lumen which has been described in the stent delivery 
section was long enough to pass through the apical access sheath (see Fig 2.13 A). After the 
tethers storage lumen being delivered transapically and exposed under direct vision, the 
dilator can be taken out by hands to expose the tethers (see Fig 2.13 B). Subsequently, the 
tethers were separated from the center lumen catheter. This catheter can also be removed from 
the stent delivery system (see Fig 2.13 C). All the above described steps can be performed by 
hands and under direct vision.  
 
 
 
 
 
Fig 2.13  A: The fixation tethers storage lumen is longer than the apical access sheath and it can pass through the sheath. B: 
The tethers can be exposed under direct vision after taking the dilator off. C: The center lumen catheter was dismounted from 
the delivery system and the tethers were exposed completely. 
 
 
22 
 
2.5.5 The AmplatzerTM
The Amplatzer
 septal occluder and deployment of the occluder 
TM septal occluder is composed of two small disks of different sizes with a slim 
cylindrical middle waist (see Fig 2.14). The disks consist of a double-layer wire mesh made 
from Nitinol alloy. It is wildly used to treat atrial septal defects (ASD) and ventricular septal 
defects (VSD). The occluder can be stretched in to a thin rod and delivered into the heart by 
transcatheter technique.  
 
 
 
 
Fig 2.14  A, B: AmplatzerTM septal occlude. C: The occluder can be stretched into very thin diameter. 
 
 
In our system, after the tethers capture, the AmplatzerTM occluder was threaded by the three 
fixation tethers and the guide wire (see Fig 2.15 A). The small disk faced towards the apex. 
Then the threaded occluder was pushed towards the apex through the apical access sheath (see 
Fig 2.15 B). The pushing was stopped when the distal part of the occluder got out of the 
sheath and expanded into a disk in the left ventricle (see Fig 2.15 C). Subsequently, the apical 
sheath was pulled back until being totally removed from the heart. Thus, the big disk 
expanded on the outer side of the apex and the deployment of the occluder was finished (see 
Fig 2.15 D). Throughout this process, the fixation tethers were pulled slightly to keep them 
straight. The smaller disk covered the inner side of the apical defect and the larger one 
covered the outer side, while the waist between the two discs plugged the hole. 
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Fig 2.15  A: The three fixation tethers and the guide wire were thread through the occluder. B: The occluder was collapsed 
and loaded into the apical access sheath and pushed into the heart by a pusher (a). C, D: The pushing stopped when the distal 
part got out of the sheath, and then the apical sheath was pulled back till it was totally removed from the heart. (In these 
pictures, the apex was simulated by a small silicon pad.) 
 
 
2.5.6 Stent deployment and tensile test on the occluder system 
The performance of stent deployment followed the step of occluder deployment. This 
arrangement is going to be discussed in chapter 4 in more detail. In the first generation of 
stent storage and delivery system, we deploy the stent simply by pulling the tethers after 
moving the tip of the delivery system to the center of the mitral annulus. However, in the 
second and third generations, the tip which covered the opening of the system should be 
pushed around 1 cm forward to open the delivery catheter before stent deployment. In all of 
the three systems, the only motive force for the stent deployment was the tension on the three 
tethers. The propulsive force on the pusher simply acted on the tip for catheter opening. The 
guide wire track could be removed after the stent deployment. Then the main procedure of the 
stent implantation was finished. 
In eight porcine hearts, tensile tests on the occluder were done after the stent deployment (see 
Fig 2.16). The minimum tension for pulling the occluder out of the apex was recorded.  
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Fig 2.16  The stent (b) was connected with the Newton meter (d) by the three fixation tethers (c). The Newton meter was 
pulled until the occluder (a) was dragged out of the apex. 
 
 
2.5.7 Apical access sheath unit 
In this mitral valved stent implantation system, the apical access sheath played a very 
important role. Most of the steps were performed via this sheath. Devices of different sizes 
and shapes were pushed into or pulled out of the heart through this sheath. Furthermore, in 
future in vivo experiments, this sheath should also work as a blood stream blocker. Clinically, 
these kinds of sheath always have a valvular end to block the blood stream. Catheters with 
smooth and simple shape can go in and out the valvular end very easily. But in our systems, 
we used devices such as hooks, magnets and tethers. It was difficult for these devices to go 
through this valve from inside of the sheath. Besides, in our system, the occluder should be 
inserted into the radial sheath, the valve on the end of the sheath also became an obstacle for 
the occluder. So, we designed and made a special apical access sheath for our implantation 
system and developed it according to different generations of the systems (see Fig 2.17). 
A 10 Fr access sheath is the main part of this apical access unit. The second part is a 3 cm soft 
silicon tube (10-Fr inner diameter) which was attached onto the end of the sheath. These two 
parts were always fixed on the apex throughout the implantation. The third part was 
detachable. It consisted of a valvular end (see Fig 2.17 A) or an end with a lid (see Fig 2.17 B). 
The former was used in the first and the second generations of the systems. It should be taken 
off after the tethers capture step. The latter one was used in the last generation. It should be 
taken off when the operator saw the dilator on the tip of the delivery system get out from the 
apical radial sheath. Afterwards, the silicon tube could be clamped to stop the blood stream. 
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Fig 2.17  A: The apical access unit with a detachable valvular end. B: The apical access unit with a detachable lid. 
 
 
2.6 In vitro water circulation system and prototype test system 
Due to simplification of the transvenous-transseptal access in the in vitro study, we performed 
the test on our system via a left-transatrial access. For the evaluation, we established an in 
vitro water circulation system (see Fig 2.18). 37°C water was continuously pumped into the 
left atrium via a sheath at velocity of 1l/min by a rotary pump. The outflow from the aorta was 
gathered by a 51 cm×36 cm×15 cm uncovered acryl glass box and emptied into the water 
recycle pool for circulation. 
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Fig 2.18 The in vitro circulation system. a: Acryl glass box; b: Water recycle pool; c: Rotary pump; d: Porcine heart and its 
fixation system. 
 
All tests were conducted on porcine hearts which were received from a local slaughterhouse. 
Each heart was fixed in the center of the acryl glass box. A 20 cm entrance sheath for the stent 
delivery system was inserted into the left atrium via one of the pulmonary vein and fixed. The 
other pulmonary veins were closed. This sheath was modified from a 19 Fr vascular access 
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sheath. In the tests which were performed under endoscopic view, this sheath was an entrance 
for the endoscope. In those cases, another sheath of the same type was stuck and fixed in the 
middle of the left atrium wall. Water was pumped into the left atrium via one of these sheaths 
(see Fig 2.19).  
 
 
 
Fig 2.19  a: Water and endoscope access sheath; b: Access sheath for the balloon catheter for track establishment as well 
as the stent delivery catheter. 
 
 
2.7 Prototype evaluation and optimization 
The first generation prototype was designed and produced for percutaneous mitral valved 
stent implantation. The prototype was tested in the in vitro system which we have mentioned 
above. General operability of each part of the system was evaluated. Different parts of the 
prototype were improved as soon as problems appeared in the in vitro evaluation. So, the 
prototype was developed and optimized into next generations until the final third generation. 
This final prototype was further evaluated quantitatively in the following. 
 
 
2.8 In vitro tests on the latest prototype 
The third generation prototype was the optimal generation in this in vitro study. It was tested 
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respectively eleven times under endoscopic view and x-ray visualization in the in vitro 
circulation system. Durations and rate of success of each procedural step were recorded. 
According to these tests, the feasibility of this in vivo test was evaluated. 
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3. Results 
 
 
3.1 Femoral vein-apex guide wire track establishment system 
The magnet capture system was tested in ten porcine hearts. All the balloon catheters were 
caught by the magnet in all cases (10 of 10) (see Fig 3.1). The average duration of balloon 
catheter capturing was 120 seconds (n = 8; see Table 3.1). But problems occurred in 2 of 10 
hearts. As we know, for keeping the pressurization of the heart, valvular end had to be added 
on all sheaths indwelt on the heart. These ends prevent water running out from the sheaths in 
order to keep the pressurization in the heart. But the difficulty of pulling the magnets out of 
the sheaths was also increased because of the valve. In 2 cases, the magnets were blocked by 
the valve and dropped off from the tip of the balloon catheter into the hearts. 
 
 
 
Fig 3.1 A, B: The magnets caught each other under endoscopic view. (a: the stick with the magnet on the tip; b: the 
magnet on the tip of the balloon catheter). C, D: The magnet capture was successfully performed under X-ray visualization. 
(a: the balloon catheter; b: the capture stick; c: the magnets). 
 
On the other side, the commonly clinically used snare capture system worked perfectly in this 
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in vitro study under endoscopic and X-ray visualization (see Fig 3.2). All the capture attempts 
were successfully performed in 22 of 22 hearts. The average duration of snare capture was 
271 sec. No device failure happened (see Table 3.1) during the trials.  
 
 
 
 
Fig 3.2  A, B: snare capture under endoscopic view. C, D: snare capture under X-ray visualization. 
 
Table 3.1Comparison of two track establishment systems 
Method Success Rate Duration(sec) Problems 
Magnet capture system 10/10 120 Magnet abscission 
Snare capture system 22/22 271 None 
 
 
3.2 Storage and delivery system for the stent and the fixation tethers 
The prototype of the first generation was tested four times in our study. Stent and tethers were 
successfully loaded into the catheter. In two of the four cases, the entire bundle of tethers was 
pulled out of the storage catheter at the same time and blocked the transapical access (see Fig 
3.3 A). The tethers could not get into the apical radial sheath orderly. In the other two cases, 
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the tethers bundle even cannot get through the lip (see Fig 3.3 B).  
 
 
 
Fig3.3  A: The tethers could not get into the apical access sheath. B: The tethers were blocked in the storage catheter by 
the silicon lip. 
 
The second generation worked better but not well enough. It was tested for six times, the last 
two hearts were done under endoscopic view in the in vitro circulation system. In 4 of 6 hearts, 
the tethers were smoothly pulled out. But in the other two hearts, the tethers were hampered. 
In one of these two hearts, too much tether released off at the same time and blocked the 
apical access sheath (see Fig 3.4 A). In the other heart, the last rounds of the tethers twined 
around the center lumen and cannot be moved anymore because of the friction and the 
resistance of the tip (see Fig 3.4 B). This situation was observed under endoscopic view. 
 
 
 
Fig 3.4  A: The fixation tethers blocked the apical access sheath. B: The last rounds of the tethers twined round the center 
lumen and cannot be moved anymore. 
 
The third generation was tested in 22 hearts. In all hearts, the tethers were successfully 
delivered within the heart, smoothly and orderly. Table 3.2 lists a comparison between the 
three generations. 
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Table 3.2 Comparison between the fixation tethers storage and delivery systems 
Prototype 
Generation 
Success rate of 
tethers loading 
Success rate of 
tethers straightening 
Problems 
1st 4/4  generation 0/4 unordered tethers clew 
2nd 6/6  generation 4/6 unordered tethers clew; 
insufficient straighten of 
the tethers 
3rd 22/22  generation 22/22 None 
 
 
3.3 Fixation tether capture system 
The tests on the hook-loop system were performed in four hearts. In 3 of 4 hearts, the loop 
was successfully caught by the hook. But unfortunately, due to the problems with the first 
generation of the tethers storage system, the loop-hook structure was not strong enough to 
pull the clew of tethers out. Finally, all of these three loops were broken owing to too much 
force. In one heart, the loop was collapsed and closed because of the surface tension of the 
liquid. It was impossible to pass the hook through the loop.  
The forceps-magnet-loop system was tested six times. In all the six hearts, the loops were 
caught by the forceps (see Fig 3.5 A). In 4 of 6 hearts, the loops were successfully pulled out 
of the apical sheath. In the other two hearts, the loops were broken because they were not 
strong enough to overcome the obstruction of the tethers. It took in average 157 sec from the 
beginning of tethers capture to all the tethers being straightened. No endocardium, chordae 
tendineae or mitral valve damage was observed.  
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Fig 3.5  A: The forceps caught the magnet under endoscopic view. B: The forceps held the magnet on its tip. C, D: The 
forceps was pushed a few centimeters forward to catch the loop behind the magnet. E: The forceps caught the loop and it was 
pulled into the apical access sheath. 
 
As mentioned above, the hand capture system worked well in all the 22 hearts. Average 
duration of the capture procedure was 36 sec. Comparison of three generations of tethers 
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capture system are listed in Table 3.3. 
 
Table 3.3 Comparison of three tethers capture system 
Method Success Rate Duration (sec) Problems 
Hook-loop system 0/4 N/A loop break;  
invisible procedure under 
direct vision or X-ray 
Forceps-magnet-loop 
system 
4/6 157 loop break 
Hand capture system 22/22 36 None 
N/A=Not available 
 
 
3.4 Tensile test on the deployed occluder 
In eight hearts, we did the tensile test on the deployed occluder. The mean minimal tension for 
dragging the occluder out of the apex was 29 N (from 17.5 N to 39 N) (see Table 7.1 in 
appendix section). 
 
 
3.5 In vitro overall evaluation of the latest prototype 
The optimized prototype was tested under endoscopic view and X-ray visualization for 11 
times, respectively. The average durations of the whole in vitro implantation procedure were 
11 min 30 sec under endoscopic and 10 min 47 sec under X-ray visualization. Average 
durations of the main steps of the implantation under endoscopy and X-ray are listed in Table 
3.4.  
 
Table 3.4 Durations of the main steps of in vitro implantation 
 Duration 
under endoscopy under x-ray 
Track establishment 5 min 06 sec 3 min 55 sec 
Stent delivery and tethers capture 2 min 56 sec 1 min 45 sec 
Occluder deployment 1 min 46 sec 1 min 21 sec 
Stent deployment 0 min 20 sec 0 min 41 sec 
Overall procedure 11 min 30 sec 10 min 47 sec 
 
The positioning of the stent was classified into 6 grades (I=excellent; II=good; III=not bad; 
IV=not well positioned, but most part of the stent was in the mitral annular; V=not well 
positioned and most part of the stent was out of the mitral annular; VI=the whole stent was in 
the left atrium or the left ventricle; see Table 3.5). In the tests under endoscopy, 10 of 11 stents 
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were excellently positioned (see Fig 3.6). One stent got a good position. The stent position 
after 8 of 11 implantations under X-ray were classified as grade I, in two cases as grade II and 
in one case as grade I. 
 
 
 
 
Fig 3.6 A: Stent position under endoscopy. B: Stent position under X-ray. 
 
Table 3.5  Stent position classification under endoscopy and X-ray 
 Number 
Under endoscopy Under X-ray 
Class I 10 8 
Class II 1 2 
Class III 0 1 
Class IV 0 0 
Class V 0 0 
Class VI 0 0 
Total 11 11 
Class I=excellent; Class II=good; Class III=not bad; Class IV=not well positioned, but most part of the stent was in the mitral 
annular; Class V=not well positioned and most part of the stent was out of the mitral annular; VI=the whole stent was in the 
left atrium or the left ventricle. 
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In all of the 22 hearts, the occluder was well deployed and the position was excellent. But in 7 
of 22 cases, the occluders could not be delivered along the fixation tethers and the guide wire 
smoothly. In four cases of them, the occluders even could not be pushed any more unless the 
tethers were released. The tethers could be straightened again after the occluder deployment. 
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4. Discussion 
 
 
4.1  Self-expandable nitinol stent 
In 2005, Boudjemline, Ma and their groups have demonstrated the feasibility of transcatheter 
atrioventricular valved stent implantation. They respectively fixed the stent by jamming the 
atrioventricular annulus between two crowns and disks (Boudjemline et al., 2005) (Ma et al., 
2005). In Boudjemline’s study, neither echographic nor angiographic leakage was detected 
after percutaneous tricuspid valved stent implantation in 7 of 8 animals (Boudjemline et al., 
2005). Theoretically, these stents do not need any other anchorage systems for stent fixation; 
these kinds of stent structure were more suitable for percutaneous implantation. But Ma’s 
study showed that this stent fixation was not enough to prevent PVL’s in mitral position. In 
their study, no stent migration was observed but severe PVL’s were reported (Ma et al., 2005). 
We may summarize the reasons then as follows: 
1. The native mitral annulus is not exactly circular. The gap between the stent and the native 
annulus has to be covered by the stent. 
2. The maximal pressure in the left ventricle is much higher than that in the right ventricle. 
The stent fixation is not strong enough for PVL prevention. 
3. Contraction of the left ventricle is more powerful than that of the right heart and the 
consequent deformation of the annulus is more violent. The double disk or double crown 
structure decreases the compliance of the stent, especially the compliance of its annulus 
element. 
4. Expanding of ventricular disk of the stent is restricted by the native mitral valve and its 
chordae tendinae. Consequently, the ventricular disk of the stent cannot provide optimal 
force for anchoring the stent in mitral annulus during ventricular systole. The risks of stent 
migration and PVL are increased. 
Having these reasons in mind, in this in vitro study and the planned consequent in vivo study, 
we decided to use the stent with tethers for better stent fixation and PVL prevention. It had 
been demonstrated excellent in both, mitral and tricuspid, positions in our previous studies. 
However, as a result, the tethers storage and fixation presented an obstacle with regard to 
percutaneous valved stent implantation. It will be discussed in the part of stent storage and 
delivery system. 
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4.2 Device development 
 
 
4.2.1 Femoral vein-apex guide wire track establishment system 
Anyhow, the magnet system worked well in the heart, even better than the snare capture 
system in most of the cases. In our study, the magnet was fixed onto the tip of the balloon 
catheter by 5-0 polypropylene sutures, a small metallic ring (1 mm in diameter, 0.5 mm in 
thickness) and super glue. It was proven that this fixation was not strong enough to pass the 
valve at the end of the interventional devices. It is possible to make the fixation of the magnet 
much stronger by technical and material improvements, for example by an additional 
covering of the balloon catheter. Then we can pull the magnet into this sheath before we pull 
the whole balloon catheter out. So, the magnet could be protected. But the methods above 
increase material cost and more than that-compared to the snare capture system-they are more 
complicated. An easier structure always means higher efficiency and less risk. For these 
reasons, we chose the snare capture system in our study as the optimal one. 
But capture with magnets was a good idea anyway and it worked really well in the heart. It 
may even have more advantages in smaller chambers than the snare capture system such as in 
vessels and hearts of infants. This technique is well worth developing. First of all, the catheter 
structure and craftsmanship should be improved. 
 
 
4.2.2 Storage and delivery system for the stent and the fixation tethers 
 
The first generation prototype 
The in vitro tests on this system showed that the clew of tethers was blocked in the left 
ventricle or even in the storage catheter. So, the problem occurred how to store three 75 cm 
long tethers in a 4 cm long 14 Fr catheter and make sure that they can be pulled out orderly. 
Another problem of this prototype was its unstreamlined configuration. As described above, 
we used a 14 Fr flap-like lip and a 6 Fr conical tip to cover the top of the catheter. The 
different sizes of these two parts lead to unstreamlined configuration. As mentioned, the tip 
should be detachable and small enough to pass the 10 Fr apical access sheath while the lip 
should be large enough to cover the top end of a 14 Fr catheter. It was not achieved to produce 
these two structurally and functionally separated parts into a continuous whole. But obviously, 
the non-continuous configuration increased the resistance especially in the case of passing the 
atrial septum (see Fig 4.1). 
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Fig 4.1  The silicon lid could not smoothly pass the septum (the white arrow). 
 
Furthermore, another reason why we chose the lip structure is that it didn’t occupy any space 
inside the catheter and then there would be enough capacity for containing the tethers. For the 
passage of the stent, we made a ‘Y’ shaped incision on the lip. So the stent and tethers storage 
catheter was not totally sealed. In addition, when the tip meets the resistance of the septum, 
the incision could easily be opened by the pressure on the tip (see Fig 4.2). This increased the 
risk of tethers releasing from the catheter too early. The non-continuous configuration and 
unstable connections would probably become obstacle for the transseptal approach. 
 
 
 
Fig 4.2  The conical lid could be easily pressed into the catheter. 
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In summary, the main reason which led to these problems is the storage of the three 75 cm 
long tethers. The tethers should occupy as less space as possible and have to be pulled out of 
the storage catheter orderly. Accordingly, in the prototypes of following generations, storage 
of the tethers should be primarily taken into account. 
 
 
The second generation prototype 
In this prototype generation, the tethers were wound around the center lumen instead of being 
folded into a bundle. The tethers were orderly wound from the bottom to the top so they can 
be pulled out the other way round. More than that, the needed space for the tethers was 
effectively minimized because of the helical structure. 
As a result, the change made it possible to use a larger conical tip (14 Fr in maximum 
diameter) instead of the lip to seal the catheter. The role of the small conical tip was replaced 
by a small detachable tube as described above. Though this tip occupied some space in the 
catheter, the remaining space was enough for the tethers. More important, the configuration of 
this prototype was much more streamlined than that of the first generation. And, obviously, 
this generation was much more robust. The tethers were prevented from releasing because the 
catheter was totally sealed. 
Beyond all questions, there was a great improvement on the prototype, especially on the tip. A 
stable tip structure was formed. But problems still remained on the tethers storage system.  
In our tests on this prototype, in 4 of 6 hearts the tethers were successfully pulled out, and the 
stents were deployed afterwards. But records of the endoscope showed the problems as 
follows: 
1. After catching the tethers via transapical approach, the stent storage and delivery catheter 
should be opened by pushing the pusher to open the passage for the tethers and the stent 
as well. If the catheter was opened too much, the compressed wound tethers easily 
released into the left ventricle. The clew of tethers could probably block the 10 Fr 
transapical approach. 
2. Fig 4.3 A shows that in order to straighten the last three rounds of the wound tethers, the 
tethers have to be wound three times around the center lumen catheter reversely. 
Otherwise, the tethers can never be straightened. Just as a spring, the number of its rings 
does not change with its length. Fig 4.3 B shows what happened in our test on the second 
generation prototype. The tethers were merely pulled but not straightened. The green part 
of the tethers was pulled out of the heart, but three rounds of the red tethers still hanged 
tight over the center lumen catheter. It is not difficult to imagine, friction increased with 
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the increasing tension. In 4 of 6 hearts, the friction was overcome and the stent was 
successfully pulled out and deployed. But in 1 of 6 hearts the stent deployment failed due 
to high friction on the center lumen catheter. 
 
 
 
 
Fig 4.3  Imagination of tethers reloading in the second generation prototype: The blue line is the center lumen of the stent 
storage and delivery system. The red line and the green line, respectively, represent two parts of one tether. The red part is 
closer to the stent. The purple line represents the apex. The pictures show that we have to wind it while pulling in order to 
straighten the tether (A). Otherwise the red part of the tethers would never be straightened but be tied around the center 
lumen (B). 
 
To conclude, tests on this prototype indicated that although the helical tethers storage system 
minimized the needed space and the tethers could be pulled out orderly. But problems 
occurred during the stent deployment. Besides, tethers releasing automatically when the 
storage catheter was opened too much was another problem. The tethers storage system was 
improved and lead to the next generation. 
 
 
The third generation prototype 
In this prototype generation, the tethers were stored within a 37 cm long tethers storage lumen 
which was composed of an inner 35 cm center lumen catheter and an outer 37 cm dilator. The 
tethers were straightened and folded into half. Consequently, they were stored in the lumen 
between the two catheters. Both of the catheters were long and thin enough to pass through 
the 10 Fr apical access sheath and could easily be removed. 
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This unit delivered the tethers out of the chest in all hearts (22 of 22 hearts). Because the 
tethers were kept straight in the storage lumen, they were not able to move or be out of shape 
till the dilator has been removed. Accordingly, the tethers releasing during delivery and 
capture was successfully avoided.  
After taking the dilator off transapically, three tethers and the center lumen catheter were 
clearly exposed under direct vision. What we only have to do was to straighten the folded 
tethers and take the center lumen catheter off. Thus the three 75 cm tethers which had 
troubled us in the past two generations were under control, straightly and orderly. 
In addition, as mentioned above, the center lumen catheter was cut off from the arterial pig 
tail catheter, and the dilator was made from soft silicon. Therefore, these units would be soft 
and strong enough to be delivered along the femoral vein-septum-apex track and pass the 
septum in the planned in vivo study. 
 
 
Summary 
A clear improvement in the operative process in mitral valved stent implantation could be 
observed throughout the development of this functional unit resulting in the third prototype 
generation. For this, the key improvement was the change of the tethers storage technique. 
Accordingly, the tip was transformed into different shapes or lengths. The tethers storage 
lumen outside the stent delivery catheter nicely resolved the problems of tethers storage and 
capture which we are going to discuss in the next part. 
 
 
4.2.3 Fixation tether capture system 
 
The first generation capture system: “hook-loop” system 
As described in the materials and methods part, in this generation, the loop on the tip of the 
delivery system was captured by a hook. Because the loop made from 3-0 polypropylene 
suture was non-visualized under X-ray, it was very difficult to catch the loop in the left 
ventricle by a hook. So, the tip was delivered into the apical 10 Fr access sheath before 
capturing. That means the loop capturing was conducted in limited space. It was supposed to 
increase the success rate of tethers capture.  
The tests on the loop-hook system showed a good capture rate, but also indicated two main 
problems of this system. Firstly, the polypropylene suture was not strong enough to sustain 
high tension. Secondly, stronger sutures such as silk ones were unsuitable for this system 
either, because their softness makes them impossible to keep the loop open in the blood. In 
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some cases, they were not stiff enough to resist the surface tension of the liquid. 
Furthermore, for the hook-shaped applicators, valves on the end of the sheath were always 
obstacles. The hook can easily get into the sheath but it is difficult to pull it out. The paradox 
was that a valve-like end was necessary in the loop-hook system for blocking the blood 
stream. Other blood blocking methods such as clamp locking device can perfectly stop 
bleeding but the hook movability was also restricted. 
 
 
The second generation capture system: “forceps-magnet-loop” system 
The magnet on the loop made it easier for the forceps to catch the loop. As soon as the forceps 
were delivered into the left ventricle, the magnet automatically attached to the tip of the 
forceps automatically because of magnetic force. The forceps can easily catch the loop after 
moving a little forward. 
Both, the magnet and the forceps were visible under X-ray. It was possible to monitor the 
whole capture procedure under X-ray and the procedure could be conducted in the left 
ventricle. Compared with the first generation of capture systems, this system is visible and 
controllable. And with the development of the tethers storage system, the whole capture 
processes were successfully performed in 4 of 6 hearts. Moreover, the forceps - especially 
designed for interventional operation - were smooth enough to pass the valve-like end of the 
sheath in both directions. 
The forceps-magnet-loop system is more efficient than the hook-loop system. However, due 
to the inherent defect of the suture loop, it is risky to conduct the capture with this system in 
vivo. If the loop is broken in the heart or the apical sheath and the tethers are only be partly 
released, there would be immense problems, because neither picking the tip out via apical 
access nor pulling all the devices back via venous approach would be feasible at that time. 
Nothing could be done to retrieve the situation transcatheter-based and the procedure has to 
be converted into an open surgical one by enlarging the apical access. 
In conclusion, the suture loops method had to be exchanged and the next generation of tethers 
capture system should be safer and more efficient. 
 
 
The third generation capture system: “hand capture” system 
As mentioned above, this generation of tethers capturing system was tested in 22 hearts. In all 
hearts, the tethers storage lumens could smoothly guide the tethers out of the heart via the 
apical access. Afterwards, the procedure of tethers capture was performed without any help of 
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devices under direct vision and completed in a short period of time. All the tethers were 
slightly and successfully captured by hands, no device damage happened. The procedure from 
the tethers storage lumen getting into the apical radial sheath to the center lumen being taken 
off took averagely 36 sec. 
With this system, neither stent delivery nor tethers capture had to be monitored under X-ray or 
endoscopy. Appearance of the tethers storage lumen in the apical sheath was a very clear 
visible signal. Due to absence of operations in the heart, no endocardium, chordae tendinae 
nor mitral valve damage was detected after implantation. It showed the high safety and 
controllability of this system.  
In addition, the valvular end of the apical sheath could be replaced by a clamp lock device in 
this system. The dilator of the tethers storage lumen matched with the apical access sheath 
size, thus the blood stream was blocked by the dilator during the tethers capture. After taking 
off the storage lumen, the apical sheath could be clamped, and the following occluder loading 
could be conducted outside the body. The apical sheath should be kept close until occluder 
deployment started. 
 
 
Summary 
All of these three generations have good success rate in the capture of tethers. But owing to 
the problems of the tether storage system, all the tests on the first generation and 2 of 6 tests 
on the second generation were not completed. However, these two generations had one fatal 
disadvantage: the fragile suture loops. Breaking of the loop would probably lead to open chest 
operation or another non-correctable situation. 
No endocardium, chordae tendineae nor mitral valve damage was detected in any heart after 
implantation. In the loop-hook system, the loops were caught in the apical radial sheath. The 
hook did not touch any parts of the heart, and, therefore did not injure the heart. Similarly, the 
third generation is absolute harmless to the heart, it does not even have any invasive 
components. Although no heart damage was detected in the tests on the forceps-magnet-loop 
system, the possibility of heart damage cannot be ruled out. Because, in this system, the 
tethers capture was conducted in the left ventricle and the metallic forceps with serrated bite 
match is invasive anyway. 
Another factor has to be taken into consideration is the compatibility of the tethers capture 
system and the apical access sheath. It is one of the most overlooked points in the in vitro 
experiments, because there was no real blood stream in the tests. But in the in vivo 
experiments, low compatibility of these two parts would result in massive blood loss. For the 
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loop-hook system and the forceps-magnet-loop system, we had to fix a valvular end onto the 
apical sheath. And it should be detachable, because it would also block the occluder 
deployment. This valvular end blocked the bloodstream, and was not restrictive for the 
movability of the hook and the forceps. After tethers capture, the valved blocker had to 
removed and replaced by a clamp lock.  
In contrast, the third generation was simpler and more convenient. What one had to do was to 
open the clamp lock, take the tethers storage lumen out and clamp the sheath again. Simple 
but efficient structure minimized blood loss as well as uncertainty arising from complicated 
devices and operations. 
Besides, the second generation took more than 4 times longer than the third one. In summary, 
the hand capture system is safer and more efficient than the former generations. In other 
words, it would be more practicable in the planned in vivo experiments.  
 
 
4.3 The AmplatzerTM
 
 septal occluder 
4.3.1 Occluder deployment 
All occluders were nicely deployed within a short time in our tests (see Fig 4.4). That showed 
us the feasibility to perform the same procedure on a beating heart. But to push the occluder 
along the tethers and track was sometimes difficult in our in vitro tests. This problem was 
observed in 7 of 22 hearts. In 4 of these hearts, this problem was particularly serious. 
However, as noted in the results part, after releasing the ends of the tethers, the occluder could 
be pushed together with the tethers. Afterwards, the tethers could be easily straightened again 
by pulling their ends. So, in case of the situation above, the stent had to be kept in the storage 
catheter until the occluder deployment being finished. Otherwise the stent would probably be 
driven out of its position by the blood stream after the tethers were released.  
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Fig 4.4  A: The macro view on the apex after occluder deployment. B: Endoscopic view from atrial side on the occluder. 
C: The small disk of the occluder was pushed into the heart and expanded. D: Afterwards, the apical access sheath was taken 
off and the big disk of the occluder expanded. 
 
 
4.3.2 Tensile test on the deployed occluder 
The tensile tests on the occluders in 8 hearts indicate the feasibility of the amplatzer occluder 
to hold the mitral valved stent in position. In the in vivo study on the transapical mitral valved 
stent implantation of our research group, the similar tensile test on the tethers and the stent 
was also conducted. The results showed, in normal porcine hearts, the range of tension on the 
stent to keep it in position is from 3.2 N to 5.7 N (4.5 N in average) (see Fig 4.5). In this in 
vitro study, the occluder could stand forces from 17.5 N to 39 N (29 N in average) before 
being pulled out of the apical defect. Therefore, it is reasonable to say that the occluder is able 
to hold the mitral valved stent in position in a beating heart. 
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Fig 4.5  This diagram shows the tension of a well positioned mitral valved stent on the apical fixation in a beating heart. 
 
 
4.4 Stent deployment: push or pull? 
As we know, for percutaneous heart valved stent implantation, the catheter system should be 
long and soft enough to deliver the stent and the accessories into the heart. In our system, the 
stent storage and delivery catheter have to be turned almost 180°at the septum level. But the 
softer and longer the catheter is, the more serious deformation could happen when it is pushed. 
That means, when the soft and long pusher on the venous end is pushed to deploy the stent, a 
large part of the force on the pusher just increases the deformation of the catheter but does not 
work on the stent. External load could lead to device damage if the delivery system is not 
strong enough. However, tension on the tethers from apical side can directly work on the stent. 
By pulling the tethers, the stent could be more easily deployed and the risk of device damage 
could be reduced (see Fig 4.6). 
 
 
Fig 4.6 To push the stent on the venous end (b) could lead to sever deformation of the delivery catheter. But to pull the 
stent from the apical side directly work on the stent (a). 
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4.5 In vitro tests on the latest prototype 
In vitro tests on the prototype showed that the implantation could be undergone in averagely 
11 min 30 sec under endoscopy and 10 min 47 sec under X-ray visualization. All the 22 tests 
were finished without any device damage or any other interrupt failure. This result presented 
high operability of this prototype. 
Though, in the in vivo experiments endoscopy is not practicable. The test under endoscopic 
view helped us to know how the applicator worked in the heart and how the problems 
happened in the in vitro study. 
All the stents and the occluders were deployed in position. However, in 4 of the 22 hearts, the 
positions of the stents were below the best grade. But due to the location of the native mitral 
annular in a non-beating heart is much more difficult than in a beating heart. It is possible to 
improve stent deployment in the in vivo studies. 
Moreover, as noted above, most of the occluders (in 15 of 22 hearts) could be pushed along 
the tethers and the guide wire track. And in the other seven hearts, the occluders could be 
deployed after the tethers being released. Nevertheless, various kinds of tethers should be 
tested in this system in the following study to find stronger and smoother tethers for the 
prototype. 
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5. Summary 
 
 
To date, merits of minimal invasive or non-invasive aortic valved stent implantation in 
high-risk patients have already been demonstrated clinically by multiple registries from 
multiple centres (Webb and Wood 2012). Over 20,000 cases and over 100 publications in the 
last 10 years showed an absolute 20% increase in survival at 1 year in high-risk patients 
(Webb and Cribier 2011). 
In our study, a new idea for non-invasive mitral valved stent implantation is presented. The 
mitral valved stent and occluder was successfully connected via transspetal and transapical 
access. The duration of the whole procedure under endoscopy and X-ray was acceptable 
clinically. Especially in the implantation under X-ray, the whole procedure of in vitro 
implantation could be conducted in averagely 10 min 47 sec. For the patients determined to be 
too high risk for surgery, shorter operative duration and less invasive probably mean faster 
recovery and higher survival. 
The main techniques used in this in vitro study of percutaneous mitral valved stent 
implantation have been commonly used clinically. The history of transspetal (Allison and 
Linden 1953) and transapical puncture (Lehman et al., 1957; Levy and Lillehei 1964) on 
human is longer than 50 years. And occlusion of the defect on the left ventricle of human 
heart by AmplatzerTM Jelnin et al., 2011 occluder was conducted in 2011 ( ). 
The stent and its tethers fixation system for this in vitro study have been tested in more than 
50 porcine hearts in the in vivo study by our research group in the last 2 years. The mid-term 
observation shows it has the potential to be implanted in human heart (not yet published). 
Compared to the transcatheter mitral valved stents reported in the last few years, this system 
has less PVL and lower risk of stent migration (Lutter et al., 2009; Ma et al., 2005). 
Due to the gap between the mitral valved stent and the native mitral annulus and the difficulty 
of stent fixation, no successful transcatheter mitral valved stent implantation has been 
reported up to now. In this study, a novel mitral valved stent was used to reduce PVL and it 
was anchored onto the apex by three fixation tethers. An AmplatzerTM occluder served as an 
anchor point for the stent and occlusion for the apex defect. All the procedures were 
conducted along a femoral vein-septum-apex guide wire track. These first in vitro prototype 
tests showed good results in terms of operability and mitral stent fixation. It has a great 
potential to develop to an alternative and less invasive implantation procedure in contrast to 
transapical mitral valved stent implantation. But more data especially from in vivo trails are 
required.  
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7. Appendix 
 
 
Table 7.1 Tensile test on the depolyed occluder 
Heart Max. Force (N) 
1 38 
2 39 
3 29 
4 28 
5 17.5 
6 26.5 
7 25 
8 29 
Average 29 
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